Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares in the company, valued at approximately $47,311,236.70. This trade represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $111.13 on Friday. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s fifty day moving average is $108.09 and its 200 day moving average is $121.00. The stock has a market cap of $6.85 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 1.04 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter in the previous year, the business earned $2.68 earnings per share. Jazz Pharmaceuticals’s revenue was down .5% compared to the same quarter last year. Research analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright boosted their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Finally, Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $184.00.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Quadrant Capital Group LLC increased its position in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares during the last quarter. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter valued at $25,000. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 183 shares during the last quarter. Finally, CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth about $28,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.